C2008-09 – Novel Hydroisobenzofurans for Anticancer and/or Antibiotic Applications

Technology # 08-09 Invention for Anticancer and/or Antibiotic Applications Naturally occurring products known as 2, 11 cyclized cembranoids have been shown to inhibit the growth of KB3 nasopharyngeal carcinoma. KB3 cells are the standard cancer cell line used to test for chemotherapy effectiveness. University scientists have developed a unique synthesis process to create bicyclic hydroisobenzofurans, the beneficial compounds that are naturally occurring in 2, 11 cyclized cembranoids. These specific compounds have not previously been investigated for anticancer or antibiotic applications. To date testing has shown inhibition of growth of 50% of the KB3 cancer test cells at a concentration of the chemical compound of 3 micromolar. This invention is available for license. For interested parties seeking further information, feel free to contact: Mark Allen Lanoue Technology Manager / Tech Ventures University of Arkansas (479) 575-7243 malanoue@uark.edu Technology Ventures ventures@uark.edu 479-575-7243

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More